Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Cystic fibrosis year in review 2020: Section 2 pulmonary disease, infections, and inflammation. Pediatr Pulmonol 2022 Feb;57(2):347-360

Date

05/26/2021

Pubmed ID

34033706

DOI

10.1002/ppul.25459

Scopus ID

2-s2.0-85106317899   3 Citations

Abstract

The outlook for those with cystic fibrosis (CF) has never been brighter with ever increasing life expectancy and the approval of the highly effective CFTR modulators, such as elexacaftor/tezacaftor/ivacaftor. With that being said, the progressive pulmonary decline and importance of lung health, infection, and inflammation in CF remains. This review is the second part in a three-part CF Year in Review 2020. Part one focused on the literature related to CFTR modulators while part three will feature the multisystem effects related to CF. This review focuses on articles from Pediatric Pulmonology, including articles from other journals that are of particular interest to clinicians. Herein, we highlight studies published during 2020 related to CF pulmonary disease, infection, treatment, and diagnostics.

Author List

Antos NJ, Savant AP

Author

Nicholas Antos MD Associate Professor in the Pediatrics department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Aminophenols
Benzodioxoles
Child
Chloride Channel Agonists
Cystic Fibrosis
Cystic Fibrosis Transmembrane Conductance Regulator
Humans
Inflammation
Mutation